U.S. FDA Approves PADCEV® plus Keytruda® as Neoadjuvant and Adjuvant Treatment for Muscle-Invasive Bladder Cancer Regardless of Cisplatin Eligibility
Go back to U.S. FDA Approves PADCEV® plus Keytruda® as Neoadjuvant and Adjuvant Treatment for Muscle-Invasive Bladder Cancer Regardless of Cisplatin Eligibility| Pfizer Inc. (NYSE: PFE) | Delayed: 25.01 +0.19 (0.77%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $24.82 | 52 Week High | $37.39 | |||
| Open | $24.89 | 52 Week Low | $28.25 | |||
| Day High | $25.10 | P/E | 15.16 | |||
| Day Low | $24.75 | EPS | $1.65 | |||
| Volume | 29,775,981 | |||||
